@ztracey17@SmartPlaysDaily NFL statisticians review games for official bookkeeping but chances are probably low unless they’re being spammed to actually look at this specific play.
Original Article: Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy (phase 3 MAJESTY trial) https://t.co/dF2gb4N5q0
Editorial: A Step Forward — Obinutuzumab for Membranous Nephropathy https://t.co/eX6XAdToQ8
#Nephrology
Phase 3 MAJESTY trial: Effective therapies are needed for patients with primary membranous nephropathy. Research findings on obinutuzumab, a type II anti-CD20 antibody, are summarized in a new Quick Take video. https://t.co/7uJkzJA4Zj
@semodough Still this bullish with sibe leading the pack in B-cell modulators and pove right behind ataci? Dosing and convenience also favor sibe/pove>ataci